| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8921348 | CORCEPT THERAP | Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists |
Aug, 2028
(4 years from now) | |
| US10842801 | CORCEPT THERAP | Optimizing mifepristone absorption |
Nov, 2032
(8 years from now) | |
| US10500216 | CORCEPT THERAP | Optimizing mifepristone absorption |
Mar, 2033
(8 years from now) | |
| US10660904 | CORCEPT THERAP | Optimizing mifepristone levels for cushing's patients |
Apr, 2036
(11 years from now) | |
| US10166243 | CORCEPT THERAP | Optimizing mifepristone levels for cushing'S patients |
Apr, 2036
(11 years from now) | |
| US9943526 | CORCEPT THERAP | Optimizing mifepristone levels for cushing's patients |
Apr, 2036
(11 years from now) | |
| US10166242 | CORCEPT THERAP | Optimizing mifepristone levels for Cushing's patients |
Apr, 2036
(11 years from now) | |
| US10495650 | CORCEPT THERAP | Method for differentially diagnosing ACTH-dependent Cushing's syndrome |
Aug, 2036
(12 years from now) | |
| US10006924 | CORCEPT THERAP | Method for differentially diagnosing ACTH-dependent cushing's syndrome |
Aug, 2036
(12 years from now) | |
| US9829495 | CORCEPT THERAP | Method for differentially diagnosing ACTH-dependent Cushing's syndrome |
Aug, 2036
(12 years from now) | |
| US10151763 | CORCEPT THERAP | Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome |
Jan, 2037
(12 years from now) | |
| US10842800 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(13 years from now) | |
| US10195214 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(13 years from now) | |
| US10780097 | CORCEPT THERAP | Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
Aug, 2038
(14 years from now) | |
| US10314850 | CORCEPT THERAP | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
Aug, 2038
(14 years from now) | |
| US10231983 | CORCEPT THERAP | Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients |
Aug, 2038
(14 years from now) | |
Korlym is owned by Corcept Therap.
Korlym contains Mifepristone.
Korlym has a total of 16 drug patents out of which 0 drug patents have expired.
Korlym was authorised for market use on 17 February, 2012.
Korlym is available in tablet;oral dosage forms.
Korlym can be used as treating cushing's syndrome.
The generics of Korlym are possible to be released after 22 August, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-22) | Feb 17, 2019 |
| New Product(NP) | Feb 17, 2015 |
| Orphan Drug Exclusivity(ODE) | Feb 17, 2019 |
Drugs and Companies using MIFEPRISTONE ingredient
Market Authorisation Date: 17 February, 2012
Treatment: Treating cushing's syndrome
Dosage: TABLET;ORAL
KORLYM family patents
